Dr. Reddy’s Laboratories Q3 Performance Update The pharmaceutical major reported a **14% YoY** decline in net profit, which fell to **Rs 1,210 crore**. Despite the drop in earnings, total revenue climbed **4%** to **Rs 8,727 crore**. Operational headwinds were driven by lower margins and a specific downturn in the North American market, where sales contracted by **12%**. This weakness was partially mitigated by robust performance in other regions. The company saw strong growth momentum across **India**, **Europe**, and **Emerging Markets**.